References
- AaproMSBohliusJCameronDA2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumoursEur J Cancer201147183221095116
- KlasterskyJde NauroisJRolstonKManagement of febrile neutropaenia: ESMO Clinical Practice GuidelinesAnn Oncol201627suppl 5v111v11827664247
- KudererNMDaleDCCrawfordJCoslerLELymanGHMortality, morbidity, and cost associated with febrile neutropenia in adult cancer patientsCancer2006106102258226616575919
- WangLBaserOKutikovaLPageJHBarronRThe impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trialsSupport Care Cancer201523113131314025821144
- SmithTJBohlkeKLymanGHRecommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline updateJ Clin Oncol201533283199321226169616
- CrawfordJArmitageJBalducciLMyeloid growth factorsJ Natl Compr Canc Netw201311101266129024142827
- CrawfordJCasertaCRoilaFESMO Guidelines Working GroupHematopoietic growth factors: ESMO Clinical Practice Guidelines for the applicationsAnn Oncol201021Suppl 5v248v25120555091
- SmithTJKhatcheressianJLymanGH2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guidelineJ Clin Oncol200624193187320516682719
- CrawfordJOzerHStollerRReduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancerN Engl J Med199132531641701711156
- PettengellRGurneyHRadfordJAGranulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin’s lymphoma: a randomized controlled trialBlood1992806143014361381626
- Trillet-LenoirVGreenJManegoldCRecombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapyEur J Cancer199329A33193247691119
- Nivestim™ (filgrastim) [summary of product characteristics]2017 Available from: https://www.medicines.org.uk/emc/medicine/23174Accessed March 5, 2017
- WallerCFSemiglazovVFTjulandinSBentsionDChanSChallandRA phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancerOnkologie2010331050451120926897
- SchwartzbergLSLalLSBaluSClinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing ChemotherapyJ Manag Care Spec Pharm201819
- BongiovanniAMontiMFocaFRecombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR)Support Care Cancer201725111111727568305
- Eldar-LissaiACoslerLECulakovaELymanGHEconomic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapyValue Health200811217217918380630
- JamesETrautmanHSzaboETangBComparative cost-efficiency analysis of granulocyte colony-stimulating factors for use in chemotherapy patients in the United StatesBlood2017130Suppl 14667
- SunDAndayaniTMAltyarAMacdonaldKAbrahamIPotential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation studyClin Ther201537484285725704107
- JamesETrautmanHSzaboETangBBudget impact analysis of switching chemotherapy patients using granulocyte colony-stimulating factors (G-CSFs) from pegfilgrastim to short-acting G-CSFs in the United States [Abstract 4668]American Society of Hematology2017